Adaptive Biotechnologies Financial Statements (ADPT)
|
|
|
|
Report date
|
|
|
24.02.2021 |
15.02.2022 |
14.02.2023 |
31.12.2023 |
29.02.2024 |
|
07.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
98.4 |
154.3 |
185.3 |
170.3 |
170.3 |
|
177.3 |
|
Operating Income, bln rub |
|
|
-152.8 |
-209.0 |
-200.2 |
-201.6 |
-227.0 |
|
-166.5 |
|
EBITDA, bln rub |
? |
|
-144.3 |
-193.3 |
-168.0 |
-179.4 |
-189.3 |
|
-163.5 |
|
Net profit, bln rub |
? |
|
-139.6 |
-205.6 |
-142.5 |
-225.3 |
-225.3 |
|
-195.2 |
|
|
OCF, bln rub |
? |
|
-149.7 |
-192.7 |
-183.9 |
44.5 |
-156.3 |
|
-109.7 |
|
CAPEX, bln rub |
? |
|
18.8 |
61.7 |
16.3 |
0.000 |
10.7 |
|
4.88 |
|
FCF, bln rub |
? |
|
-168.5 |
-254.5 |
-200.3 |
44.5 |
-167.0 |
|
-114.5 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
228.7 |
314.0 |
327.6 |
294.6 |
321.8 |
|
261.9 |
|
Cost of production, bln rub |
|
|
22.5 |
49.3 |
57.9 |
77.3 |
75.6 |
|
81.8 |
|
R&D, bln rub |
|
|
116.1 |
142.3 |
141.8 |
122.1 |
122.1 |
|
101.2 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
4.24 |
13.8 |
13.8 |
|
11.6 |
|
|
Assets, bln rub |
|
|
1 116 |
923.3 |
856.6 |
661.1 |
661.1 |
|
558.5 |
|
Net Assets, bln rub |
? |
|
743.3 |
604.0 |
464.2 |
308.3 |
308.4 |
|
223.8 |
|
Debt, bln rub |
|
|
107.9 |
111.7 |
108.0 |
98.8 |
229.4 |
|
91.8 |
|
Cash, bln rub |
|
|
688.3 |
353.1 |
498.2 |
346.4 |
346.4 |
|
243.3 |
|
Net debt, bln rub |
|
|
-580.4 |
-241.3 |
-390.2 |
-247.6 |
-117.0 |
|
-151.5 |
|
|
Ordinary share price, rub |
|
|
59.1 |
28.1 |
7.64 |
4.90 |
4.90 |
|
4.87 |
|
Number of ordinary shares, mln |
|
|
131.2 |
140.4 |
142.5 |
144.4 |
144.4 |
|
147.5 |
|
|
Market cap, bln rub |
|
|
7 759 |
3 938 |
1 089 |
707 |
707 |
|
718 |
|
EV, bln rub |
? |
|
7 178 |
3 697 |
699 |
460 |
591 |
|
567 |
|
Book value, bln rub |
|
|
614 |
476 |
338 |
189 |
184 |
|
101 |
|
|
EPS, rub |
? |
|
-1.06 |
-1.46 |
-1.00 |
-1.56 |
-1.56 |
|
-1.32 |
|
FCF/share, rub |
|
|
-1.28 |
-1.81 |
-1.41 |
0.31 |
-1.16 |
|
-0.78 |
|
BV/share, rub |
|
|
4.68 |
3.39 |
2.37 |
1.31 |
1.28 |
|
0.68 |
|
|
EBITDA margin, % |
? |
|
-146.7% |
-125.3% |
-90.7% |
-105.3% |
-111.2% |
|
-92.2% |
|
Net margin, % |
? |
|
-141.9% |
-133.2% |
-76.9% |
-132.3% |
-132.3% |
|
-110.1% |
|
FCF yield, % |
? |
|
-2.17% |
-6.46% |
-18.4% |
6.28% |
-23.6% |
|
-15.9% |
|
ROE, % |
? |
|
-18.8% |
-34.0% |
-30.7% |
-73.1% |
-73.0% |
|
-87.2% |
|
ROA, % |
? |
|
-12.5% |
-22.3% |
-16.6% |
-34.1% |
-34.1% |
|
-35.0% |
|
|
P/E |
? |
|
-55.6 |
-19.2 |
-7.64 |
-3.14 |
-3.14 |
|
-3.68 |
|
P/FCF |
|
|
-46.1 |
-15.5 |
-5.44 |
15.9 |
-4.24 |
|
-6.27 |
|
P/S |
? |
|
78.9 |
25.5 |
5.88 |
4.15 |
4.15 |
|
4.05 |
|
P/BV |
? |
|
12.6 |
8.27 |
3.22 |
3.74 |
3.84 |
|
7.12 |
|
EV/EBITDA |
? |
|
-49.7 |
-19.1 |
-4.16 |
-2.56 |
-3.12 |
|
-3.47 |
|
Debt/EBITDA |
|
|
4.02 |
1.25 |
2.32 |
1.38 |
0.62 |
|
0.93 |
|
|
R&D/CAPEX, % |
|
|
617.3% |
230.5% |
867.1% |
|
1 142% |
|
2 073% |
|
|
CAPEX/Revenue, % |
|
|
19.1% |
40.0% |
8.82% |
0.00% |
6.28% |
|
2.75% |
|
| Adaptive Biotechnologies shareholders |
